11th ESO-ESMO Masterclass in Clinical Oncology
30 ESCO credits
17.03.2012 - 22.03.2012
Ermatingen (Lake Constance), Switzerland
MASTERCLASS
Description
Chair: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: W. Gatzemeier, IT - R. Popescu, CH
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, genito-urinary, gynaecological, head and neck and lung cancers.
Spotlight sessions will facilitate compact update on haematological diseases, therapeutic management of gliomas, cancer and pregnancy, side effects of systemic treatment, oral therapy, palliative care, cancer of unknown primary, sarcoma and treatment of melanoma.
TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The Clinical Sessions will be complemented by Tumour Board discussions. Furthermore, participants will deliver case presentations within small groups and discuss these with the chairmen and the faculty.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the side effects, oral therapy and palliative care sessions will be attended jointly.
THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.
General information
ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via del Bollo, 4
20123 Milan, Italy
Ph: +39 02 85464525
Fax: +39 02 85464545
Email: fmarangoni@eso.net
CME ACCREDITATION
The Accreditation Council for Oncology in Europe (ACOE) has recommended that the event be granted 27 European CME credits.
The Masterclass has been furthermore accredited with 25 Category 1 ESMO MORA points.
ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to Union Bank of Switzerland (UBS) and Wolfsberg Centre for their consideration and support to the 2012 Masterclass.
The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are:
- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology, Merck Serono, Roche
- Silver members: Celgene Corporation, Genomic Health, Novartis Oncology and Sanofi Oncology
Faculty list
FACULTY (as of January 2012)
M. Aapro, IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH
A. Albini, IRCCS MultiMedica, Science and Technology Sector, Milan, IT
F. André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
T. Brodowicz, AKH Wien, Vienna, AT
P.G. Casali, Istituto Nazionale Tumori, Rep. di Medicina Oncologica, Milan, IT
G. Cavaletti, Università Milano-Bicocca, Dept. Neuroscience and Biomedical Technologies (DNTB), Monza, IT
G. Curigliano, European Institute of Oncology, Div. of Medical Oncology, Milan, IT
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
S. Dirnhofer, Universität Basel, Pathology Institute, Basel, CH
T. Eisen, University of Cambridge, Dept. of Oncology, Cambridge, UK
C.C. Faivre-Finn, Hospital NHS Foundation Trust, Dept. of Clinical Oncology, Manchester, UK
J.M. Fitzpatrick, Mater Hospital and University College Dublin, Dept. of Urology and Surgery, Dublin, IE
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Istituto Clinico Humanitas, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland (IOSI), Div. of Medical Oncology, Bellinzona, CH
N. Harbeck, Klinikum Grosshadern, Breast Centre of Munich University, Munich, DE
A. Horwich, The Royal Marsden Hospital, Dept. of Radiotherapy, Sutton, UK
A. Hoy, Princess Alice Hospice, Dept. Of Palliative Medicine, Epson, Surrey, UK
R. Huddart, The Institute of Cancer Research (ICR) - Royal Marsden Hospital, Division of Radiotherapy and Imaging Sutton, Surrey, UK
C.H. Köhne, Klinikum Oldenburg, Klinik für Onkologie / Hämatologie, Oldenburg, DE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Dept. of Medical Oncology, Bellinzona, CH
P. Patel, University of Nottingham, Div. Clinical Oncology, Nottingham, UK
N. Pavlidis, University of Ioannina, Div. of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
G.J. Poston, Aintree University Hospital, Dept. of Surgery, Liverpool, UK
G. Pruneri, European Institute of Oncology, Department of Pathology, and Milan University, Milan, IT
K. Redmond, Cancer World Editor, Lugano, CH
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Dept. of Haemato-Oncology, Antwerp, BE
D. Sebag-Montefiore, Institute of Oncology, St. James' University Hospital, Dept. of Medical Oncology, Leeds, UK
S. Segaert, University Hospital Sint-Rafaël, Dermatology Dept., Leuven, BE
C. Sessa, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zürich, Clinic and Policlinic for Oncology, Zurich, CH
E. Van Cutsem, University Hospital Gasthuisberg, Dept. Internal Medicine - Digestive Oncology Unit, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Department of Medical Oncology, Edegem, BE
R. von Moos, Cantonal Hospital Graubuenden, Dept. of Medical Oncology, Chur, CH
W. Weder, University Hospital Zurich, Div. of Thoracic Surgery, Zurich, CH
M. Weller, University Hospital Zurich, Department of Neurology, Zurich, CH
Programme
17 March
Participants' arrival, airport transfers, registration | |
14:30 | Clinical session Genito-urinary cancers I Chair: K. Fizazi, FR |
Prostate cancer:
| |
16:10 | Clinical session Genito-urinary cancers II |
| Bladder cancer:
Renal cancer:
|
17:50 | Coffee break |
18:20 | Tumour board Genito-urinary cancers |
20:30 | Dinner |
18 March
8:30 | Clinical session Breast cancer I |
| |
10:00 | Clinical session Breast cancer II |
|
|
10:45 | Coffee break |
| |
12:15 | Tumour board Breast cancer |
13:15 | Lunch |
14:30 | Supportive Care Session
|
15:00 | Sponsored lecture Bone health in advanced cancer patients (SPCC lecture by Amgen) R. von Moos, CH |
15:30 | Spotlight session 1 Haematological diseases |
16:30 | Coffee break |
17:00 | Sponsored lecture Management of senior ADULTS with prostate cancer - SIOG guidelines (SPCC lecture by Sanofi Oncology) J. Fitzpatrick, IE |
17:30 | Spotlight session 2 Therapeutic management of gliomas M. Weller, CH |
18:00 | Case presentations by participants |
19:30 | Dinner |
19 March
8:30 | Clinical session Gynaecological cancers |
|
|
10:30 | Coffee break |
11:00 | Clinical session Head and neck cancer |
|
|
13:00 | Lunch |
14:30 | Tumour board Gynaecological cancers |
15:00 | Tumour board Head and neck cancer |
15:30 | Sponsored lecture How to evaluate genomic Classifiers in oncology (SPCC lecture by Genomic Health) S. Dirnhofer, CH |
16:00 | Sponsored lecture The importance of the mTOR pathway in Breast Cancer treatment (SPCC lecture by Novartis) F. André, FR |
16:30 | Spotlight session 3 Cancer and pregnancy |
17:00 | Coffee break |
17:30 | Case presentations by participants (Gynaecological and head and neck cancers) |
19:30 | Dinner |
20 March
8:30 | Clinical session Gastro-intestinal tumours I |
Colon cancer:
| |
10:00 | Sponsored lecture Metastasectomies in colorectal cancer (SPCC lecture by Merk) G.J. Poston, UK |
10:30 | Coffee break |
11:00 | Clinical session Gastro-intestinal tumours II Chair: E. Van Cutsem, BE |
| |
12:30 | Tumour board Gastro-intestinal tumours E. Van Cutsem, BE - D. Sebag-Montefiore, UK - K.H. Köhne, DE |
13:30 | Lunch |
14:30 | Sponsored lecture Maintenance treatment in advanced |
15:00 | e-ESO online session on New accomplishments in breast cancer chemoprevention A. Decensi, Galliera Hospital, Genoa, IT |
16:00 | Free time |
19:30 | Dinner |
21 March
8:30 | Clinical session Lung cancer and mesothelioma I |
|
|
10:30 | Coffee break |
11:00 | Clinical session Lung cancer and mesothelioma II |
|
|
12:00 | Tumour board Lung cancer |
13:00 | Lunch |
14:15 | Joint medics and nursing session Side effects of systemic treatment and their management |
15:15 |
|
15:30 | Joint medics and nursing session Oral therapy: Adherence, compliance and drug interaction K. Redmond, CH |
16:00 | Coffee break |
16:30 | Joint medics and nursing session Palliative care |
| |
18:00 | Learning assessment tests |
19:30 | Dinner |
22 March
8:30 | Spotlight session 4 Cancer on unknown primary N. Pavlidis, GR |
9:30 | Spotlight session 5 Sarcoma P. Casali, IT |
10:30 | Coffee break |
11:00 | Spotlight session 6 Advances in systemic treatment of melanoma P. Patel, UK |
12:00 | Closure |